Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$10.82 USD
+0.05 (0.46%)
Updated Sep 25, 2024 03:37 PM ET
After-Market: $10.83 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cidara Therapeutics (CDTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$29.67 | $40.00 | $24.00 | 175.49% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Cidara Therapeutics comes to $29.67. The forecasts range from a low of $24.00 to a high of $40.00. The average price target represents an increase of 175.49% from the last closing price of $10.77.
Analyst Price Targets (3 )
Broker Rating
Cidara Therapeutics currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
8/14/2024 | H.C. Wainwright & Co. | Ed Arce | Not Available | Strong Buy |
5/16/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/25/2024 | WBB Securities | Stephen G Brozak | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 4 |
Average Target Price | $29.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | -5.22 |
CDTX FAQs
Cidara Therapeutics, Inc. (CDTX) currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Cidara Therapeutics, Inc. (CDTX) is $29.67. The current on short-term price targets is based on 1 reports.
The forecasts for Cidara Therapeutics, Inc. (CDTX) range from a low of $24 to a high of $40. The average price target represents a increase of $175.49 from the last closing price of $10.77.
The current UPSIDE for Cidara Therapeutics, Inc. (CDTX) is 175.49%
Based on short-term price targets offered by three analysts, the average price target for Cidara Therapeutics comes to $29.67. The forecasts range from a low of $24.00 to a high of $40.00. The average price target represents an increase of 175.49% from the last closing price of $10.77.